These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 23225426

  • 1. Effects of structural modifications of daunorubicin on in vitro antileukemic activity.
    Stojak M, Mazur L, Opydo-Chanek M, Lukawska M, Oszczapowicz I.
    Anticancer Res; 2012 Dec; 32(12):5271-7. PubMed ID: 23225426
    [Abstract] [Full Text] [Related]

  • 2. In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin.
    Stojak M, Mazur L, Opydo-Chanek M, Lukawska M, Oszczapowicz I.
    Anticancer Res; 2013 Oct; 33(10):4439-43. PubMed ID: 24123013
    [Abstract] [Full Text] [Related]

  • 3. Cell-cycle disturbance and induction of programmed death by new formamidine analogs of daunorubicin.
    Stojak M, Lukawska M, Oszczapowicz I, Opydo-Chanek M, Mazur L.
    Anticancer Res; 2014 Dec; 34(12):7151-8. PubMed ID: 25503143
    [Abstract] [Full Text] [Related]

  • 4. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M, Oszczapowicz I, Wietrzyk J, Opolski A, Madej J, Dzimira S, Oszczapowicz J.
    Anticancer Res; 2005 Dec; 25(3B):2043-8. PubMed ID: 16158943
    [Abstract] [Full Text] [Related]

  • 5. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes.
    Taghdisi SM, Lavaee P, Ramezani M, Abnous K.
    Eur J Pharm Biopharm; 2011 Feb; 77(2):200-6. PubMed ID: 21168488
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Antileukemic Activity of Formamidine Epidoxorubicin Analogs.
    Mazur L, Opydo-Chanek M, Śladowska K, Janota B, Kłaput U, Łukawska M, Oszczapowicz I.
    Anticancer Res; 2017 Nov; 37(11):6363-6372. PubMed ID: 29061821
    [Abstract] [Full Text] [Related]

  • 7. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
    Danesh NM, Lavaee P, Ramezani M, Abnous K, Taghdisi SM.
    Int J Pharm; 2015 Jul 15; 489(1-2):311-7. PubMed ID: 25936625
    [Abstract] [Full Text] [Related]

  • 8. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
    Kaspers GL, Veerman AJ, Pieters R, van Zantwijk I, Klumper E, Hählen K, de Waal FC, van Wering ER.
    Leukemia; 1994 Jan 15; 8(1):24-9. PubMed ID: 8289494
    [Abstract] [Full Text] [Related]

  • 9. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
    Wasowska M, Wietrzyk J, Opolski A, Oszczapowicz J, Oszczapowicz I.
    Anticancer Res; 2006 Jan 15; 26(3A):2009-12. PubMed ID: 16827137
    [Abstract] [Full Text] [Related]

  • 10. Biological properties of new derivatives of daunorubicin.
    Wasowska-Lukawska M, Wietrzyk J, Opolski A, Oszczapowicz J, Oszczapowicz I.
    In Vivo; 2007 Jan 15; 21(2):413-6. PubMed ID: 17436596
    [Abstract] [Full Text] [Related]

  • 11. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.
    Miklán Z, Orbán E, Csík G, Schlosser G, Magyar A, Hudecz F.
    Biopolymers; 2009 Jan 15; 92(6):489-501. PubMed ID: 19521976
    [Abstract] [Full Text] [Related]

  • 12. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues.
    Fan E, Shi W, Lowary TL.
    J Org Chem; 2007 Apr 13; 72(8):2917-28. PubMed ID: 17373847
    [Abstract] [Full Text] [Related]

  • 13. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
    Orbán E, Mezo G, Schlage P, Csík G, Kulić Z, Ansorge P, Fellinger E, Möller HM, Manea M.
    Amino Acids; 2011 Jul 13; 41(2):469-83. PubMed ID: 20953647
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.
    Ciesielska E, Studzian K, Wasowska M, Oszczapowicz I, Szmigiero L.
    Cell Biol Toxicol; 2005 Jul 13; 21(3-4):139-47. PubMed ID: 16328893
    [Abstract] [Full Text] [Related]

  • 15. A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.
    Orbán E, Manea M, Marquadt A, Bánóczi Z, Csík G, Fellinger E, Bosze S, Hudecz F.
    Bioconjug Chem; 2011 Oct 19; 22(10):2154-65. PubMed ID: 21950465
    [Abstract] [Full Text] [Related]

  • 16. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety.
    Perchellet EM, Sperfslage BJ, McIlvain CJ, Aligiannis N, Pouli N, Marakos P, Skaltsounis AL, Perchellet JP.
    Anticancer Res; 2001 Oct 19; 21(6A):3957-67. PubMed ID: 11911277
    [Abstract] [Full Text] [Related]

  • 17. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
    Povarov LS, Leont'eva OV, Bernaki PD, Olsuf'eva EN, Salimova EI, Pera P, Preobrazhenskaia MN.
    Bioorg Khim; 1995 Dec 19; 21(12):925-32. PubMed ID: 8602889
    [Abstract] [Full Text] [Related]

  • 18. Oxazolinodoxorubicin - a promising new anthracycline.
    Lukawska M, Klopotowska D, Milczarek M, Wietrzyk J, Studzian K, Szmigiero L, Porebska A, Oszczapowicz I.
    Anticancer Res; 2012 Jul 19; 32(7):2959-65. PubMed ID: 22753760
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
    Studzian K, Wasowska M, Piestrzeniewicz MK, Wilmańska D, Szmigiero L, Oszczapowicz I, Gniazdowski M.
    Neoplasma; 2001 Jul 19; 48(5):412-8. PubMed ID: 11845988
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of new N-substituted daunorubicin derivatives.
    Mazerska Z, Woynarowska B, Stefanska B, Borowski E, Martelli S.
    Drugs Exp Clin Res; 1987 Jul 19; 13(6):345-51. PubMed ID: 3308387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.